- Joined
- 12 January 2008
- Posts
- 7,169
- Reactions
- 17,744
Healius just torched it's shareholders by raising capital at massive discount to last close. Now -32%.
HLS - Healius Limited
- Thread starter nomore4s
- Start date
- Joined
- 20 July 2021
- Posts
- 10,978
- Reactions
- 15,244
yes i had noticed , another bullet dodged , i exited in the early stages of the take-over bidding ( i needed the CASH for a different project )
normally i would be receptive of a scrip take-over deal
however since i got out clean ( with a modest profit )
i am wondering if i should break out the calculator again , since it is a $2 discount to my exit price
i am still looking for 'healthcare exposure ' but crikey some of those debt levels
Garpal Gumnut
Ross Island Hotel
- Joined
- 2 January 2006
- Posts
- 13,344
- Reactions
- 9,450
Brave.
Very brave, though you never know with stocks.
Healius atm seems like a feeding trough for well-heeled refugees from the private schools of Sydney and that beacon of good corporate governance that was Qantas.
gg
- Joined
- 20 July 2021
- Posts
- 10,978
- Reactions
- 15,244
well the community seems to be getting unhealthier , BUT which will be survivors , and which will actually be a winner ( maybe a 20% capital gain in the next 2 years with interest rates as they are
still haven't set a target price yet ( for HLS ) but sub $1 crikey i am liable to be tempted
- Joined
- 20 July 2021
- Posts
- 10,978
- Reactions
- 15,244
Healius announces Trading Update for FY 2024
Healius Limited (ASX: HLS) today announced a trading update for FY 2024 and now expects:
• Underlying FY 2024 Earnings Before Interest Tax and Depreciation (EBITDA) of between$345 million - $350 million; and
• Underlying FY 2024 Earnings Before Interest and Tax (EBIT) of between $60 million - $65million.
Improving Pathology volumes for the half year to date have been offset by lower than expected average fees due to the softer GP market, and general inflationary pressures.
Pathology volumes for January to May have increased by 3.9% on pcp.
The transformation program for Pathology is well underway and the company expects to marginally exceed the $15m targeted net savings for FY24.
Lumus Imaging and Agilex Biolabs have continued to perform well and in line with company expectations.
ENDS
i hold HLS
gee does that $1 top up target look possible soon ??
i guess time will tell
Healius Limited (ASX: HLS) today announced a trading update for FY 2024 and now expects:
• Underlying FY 2024 Earnings Before Interest Tax and Depreciation (EBITDA) of between$345 million - $350 million; and
• Underlying FY 2024 Earnings Before Interest and Tax (EBIT) of between $60 million - $65million.
Improving Pathology volumes for the half year to date have been offset by lower than expected average fees due to the softer GP market, and general inflationary pressures.
Pathology volumes for January to May have increased by 3.9% on pcp.
The transformation program for Pathology is well underway and the company expects to marginally exceed the $15m targeted net savings for FY24.
Lumus Imaging and Agilex Biolabs have continued to perform well and in line with company expectations.
ENDS
i hold HLS
gee does that $1 top up target look possible soon ??
i guess time will tell
Dona Ferentes
A little bit OC⚡DC
- Joined
- 11 January 2016
- Posts
- 15,087
- Reactions
- 20,472
Healius has received two non-binding indicative bids for its Lumus Imaging business at around $700 million
- Joined
- 20 July 2021
- Posts
- 10,978
- Reactions
- 15,244
Sale of Lumus Imaging to Affinity Equity Partners
• Sale of Lumus Imaging for enterprise value of $965.0 million
• Completion anticipated to occur in 1Q CY2025, subject to satisfaction of certain conditions
• Proceeds from the sale will be used to reduce debt, support strategic execution in Pathology and return cash to shareholders
Healius Limited (“Healius”) (ASX: HLS) today announced it has entered into a binding agreement to sell its Lumus Imaging (“Lumus”) subsidiary to funds managed by Affinity Equity Partners for an enterprise value of $965 million on a cash, debt and equipment-lease free basis (the “Transaction”).
The Transaction is expected to result in net transaction proceeds of $835 million after the repayment of equipment leases and any closing adjustments1 and in excess of $800 million post transaction fees,separation costs and other fees.
The final proceeds will not be determined until the close of the Transaction in 1Q CY2025.
Healius does not expect to incur any tax in relation to the Transaction.
On a pre-AASB16 basis, the Transaction represents a multiple of 17.0x FY2024 EBITDA2 and 25.4xFY2024 EBIT3.
Key terms of the Transaction
The Transaction remains subject to customary conditions, including approval by the Foreign Investment Review Board.
The Transaction is not subject to financing. Subject to satisfaction of all conditions precedent, completion is expected to occur in 1Q CY2025.
To support the separation and ensure continuity for Lumus’ doctors and patients, Healius will provide Lumus with a range of transitional services, including certain IT services on commercial arm’s-length terms for a period of twelve months following completion.
Strategic rationale
As first announced in March 2024, Healius undertook a strategic review of its structure and assets with the objectives of maximising value for Healius’ shareholders while at the same time ensuring a sustainable capital structure supportive of investment and the ongoing growth in Healius’ operations.1
Closing adjustments relate primarily to working capital, lease balances and capex.2
Lumus segment underlying EBITDA of $97.3 million (post AASB 16) less AASB 16 property and equipment lease impact equating to (pre AASB 16) underlying EBITDA of $51.3 million3
Lumus segment underlying EBIT of $41.9 million (post AASB 16) less AASB 16 property and equipment lease impact equating to (pre AASB 16) underlying EBIT of $34.4 million
part of a longer release
i hold HLS
hmmm
decisions , decisions
( do nothing , reduce if a rally , or add more is a significant dip , or just hit the exit since i am about 20 cents a share in front )
• Sale of Lumus Imaging for enterprise value of $965.0 million
• Completion anticipated to occur in 1Q CY2025, subject to satisfaction of certain conditions
• Proceeds from the sale will be used to reduce debt, support strategic execution in Pathology and return cash to shareholders
Healius Limited (“Healius”) (ASX: HLS) today announced it has entered into a binding agreement to sell its Lumus Imaging (“Lumus”) subsidiary to funds managed by Affinity Equity Partners for an enterprise value of $965 million on a cash, debt and equipment-lease free basis (the “Transaction”).
The Transaction is expected to result in net transaction proceeds of $835 million after the repayment of equipment leases and any closing adjustments1 and in excess of $800 million post transaction fees,separation costs and other fees.
The final proceeds will not be determined until the close of the Transaction in 1Q CY2025.
Healius does not expect to incur any tax in relation to the Transaction.
On a pre-AASB16 basis, the Transaction represents a multiple of 17.0x FY2024 EBITDA2 and 25.4xFY2024 EBIT3.
Key terms of the Transaction
The Transaction remains subject to customary conditions, including approval by the Foreign Investment Review Board.
The Transaction is not subject to financing. Subject to satisfaction of all conditions precedent, completion is expected to occur in 1Q CY2025.
To support the separation and ensure continuity for Lumus’ doctors and patients, Healius will provide Lumus with a range of transitional services, including certain IT services on commercial arm’s-length terms for a period of twelve months following completion.
Strategic rationale
As first announced in March 2024, Healius undertook a strategic review of its structure and assets with the objectives of maximising value for Healius’ shareholders while at the same time ensuring a sustainable capital structure supportive of investment and the ongoing growth in Healius’ operations.1
Closing adjustments relate primarily to working capital, lease balances and capex.2
Lumus segment underlying EBITDA of $97.3 million (post AASB 16) less AASB 16 property and equipment lease impact equating to (pre AASB 16) underlying EBITDA of $51.3 million3
Lumus segment underlying EBIT of $41.9 million (post AASB 16) less AASB 16 property and equipment lease impact equating to (pre AASB 16) underlying EBIT of $34.4 million
part of a longer release
i hold HLS
hmmm
decisions , decisions
( do nothing , reduce if a rally , or add more is a significant dip , or just hit the exit since i am about 20 cents a share in front )
- Joined
- 20 July 2021
- Posts
- 10,978
- Reactions
- 15,244
Healius Upgraded To Neutral at JPMorgan
Healius Upgraded To Neutral at JPMorgan
In a notable turn of events, JPMorgan has recently upgraded Healius shares (ASX: HLS), a prominent player in the diagnostics and research sector, from ‘Underweight’ to a ‘Neutral’ rating, adjusting the price target to $1.65 from the earlier $1. This adjustment comes after Healius successfully...
thebull.com.au
and i took the profit ( and exited ) for about a 32 cent per share profit